| Carolyn Agnes Hammett, MD | |
|
1835 University Blvd E, Suite 226, Hyattsville, MD 20783-4600 | |
| (301) 431-4030 | |
| (301) 431-4826 |
| Full Name | Carolyn Agnes Hammett |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | 1835 University Blvd E, Hyattsville, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154331908 | NPI | - | NPPES |
| 0H36CA52078700 | Other | MD | BC MD |
| 264118 | Other | MD | UHC |
| 40090001 | Other | DC | BC DC METRO |
| 019941900 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D0039966 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Home Health Services | Silver spring, MD | Home health agency |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group Ii Llc | 0547413825 | 1776 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
| Entity Name | Privia Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013042480 PECOS PAC ID: 4385682061 Enrollment ID: O20050422000298 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000415 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
| Entity Name | Capital Healthcare Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811239627 PECOS PAC ID: 3779723309 Enrollment ID: O20130702000710 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
| Entity Name | Privia Care Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164874426 PECOS PAC ID: 3274801139 Enrollment ID: O20170616001775 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carolyn Agnes Hammett, MD 901 Sligo Creek Pkwy, Takoma Park, MD 20912-5810 Ph: (301) 431-4030 | Carolyn Agnes Hammett, MD 1835 University Blvd E, Suite 226, Hyattsville, MD 20783-4600 Ph: (301) 431-4030 |
News Archive
Obesity and diabetes have become a global epidemic leading to severe cardiovascular disease. Researchers at the University of Utah believe their recent identification of brown fat stem cells in adult humans may lead to new treatments for heart and endocrine disorders, according to a new study published in the peer-reviewed journal Stem Cells.
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Over the past few decades, hundreds of patient-advocacy organizations have emerged in the United States, promoting disease research and influencing FDA and health insurer policies.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
Can exposure to a single virus particle lead to infection or disease? Until now, solid proof has been lacking. Experimental research with insect larvae at Wageningen University and Simon Fraser University in Canada has shown that one virus particle is theoretically enough to cause infection and subsequent disease.
› Verified 2 days ago
Fisseha Yitbarek Ghidey, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4509 Garfield St, Hyattsville, MD 20781 Phone: 718-710-1813 | |
Dr. Michael Vincent Viola, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6525 Belcrest Rd, Hyattsville, MD 20782 Phone: 202-441-4545 | |
Harminder Singh Sethi, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6505 Belcrest Rd, Suite #110, Hyattsville, MD 20782 Phone: 301-779-8800 Fax: 202-636-9088 | |
Mr. Anantha K Rao, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6495 New Hampshire Ave, 190, Hyattsville, MD 20783 Phone: 301-445-4430 Fax: 301-445-3753 | |
Luke E Terry Jr., MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 8700 Central Ave Ste 204, Hyattsville, MD 20785 Phone: 301-333-3770 Fax: 301-333-3779 | |
Dr. Teresa E Allen, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6525 Belcrest Road, Suite 160, Hyattsville, MD 20782 Phone: 301-209-6250 Fax: 301-209-6204 |